Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JACQUELINE DIAZ

Allopathic & Osteopathic Physicians Family Medicine

NPI
1992991277
CMS profile
534042
Location
SUNNY ISLES BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$20.46

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $20.46 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $20.46 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JACQUELINE DIAZ

NPI 1992991277 · CMS profile ID 534042

Allopathic & Osteopathic Physicians / Family Medicine

SUNNY ISLES BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992991277?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JACQUELINE DIAZ, NPI 1992991277, CMS profile ID 534042. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992991277?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). JACQUELINE DIAZ, NPI 1992991277, CMS profile ID 534042. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992991277?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
JACQUELINE DIAZ, NPI 1992991277, CMS profile ID 534042, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1992991277?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $20.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $20.4603/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188644360 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $128.50 2
PY2024 $444.29 4
PY2025 $20.46 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $67,697.37 15
PY2024 Principal investigator $886,883.89 63
PY2023 Principal investigator $1,349,372.78 115
PY2022 Principal investigator $751,919.69 24

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

115 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Mylan Inc. $37,555.65 12/21/2023 Non-covered Recipient Entity
ORCA TRIAL LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1038726505
Principal investigator 1 Genentech, Inc. $992.00 12/15/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1040241341
Principal investigator 1 Mylan Inc. $17,180.10 12/14/2023 Non-covered Recipient Entity
ORCA TRIAL LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1038726493
Principal investigator 1 Chiesi USA, Inc. $15,655.00 12/13/2023 Non-covered Recipient Entity
BCSD RESEARCH INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051619465
Principal investigator 1 Chiesi USA, Inc. $6,000.00 12/13/2023 Non-covered Recipient Entity
BCSD RESEARCH INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051619471
Principal investigator 1 Chiesi USA, Inc. $36,024.00 12/13/2023 Non-covered Recipient Entity
BCSD RESEARCH INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051619477
Principal investigator 1 GlaxoSmithKline, LLC. $21,645.13 12/13/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1006262801
Principal investigator 1 Genentech, Inc. $5,352.00 11/29/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1040241317
Principal investigator 1 Genentech, Inc. $992.00 11/29/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1040241329
Principal investigator 1 Chiesi USA, Inc. $36,272.00 11/13/2023 Non-covered Recipient Entity
BCSD RESEARCH INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051616901
Principal investigator 1 Supernus Pharmaceuticals, Inc. $32,027.68 11/01/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5138 IN ADULTS WITH TREATMENT RESISTANT DEPRESSION No dispute reported 06/30/2026 1053193981
Principal investigator 1 Mylan Inc. $9,100.00 10/25/2023 Non-covered Recipient Entity
ORCA TRIAL LLC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1038726481
Principal investigator 1 Organon LLC $1,998.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016106613
Principal investigator 1 Organon LLC $790.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016106627
Principal investigator 1 Organon LLC $1,235.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016106641
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016106655
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016106669
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016106683
Principal investigator 1 Organon LLC $1,235.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016106697
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016106711
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016106727
Principal investigator 1 Organon LLC $1,235.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016106743
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016106757
Principal investigator 1 Organon LLC $1,235.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016106771
Principal investigator 1 Organon LLC $1,235.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112249
Principal investigator 1 Organon LLC $1,235.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112263
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112277
Principal investigator 1 Organon LLC $1,235.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112291
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112307
Principal investigator 1 Organon LLC $1,235.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112321
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112335
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112349
Principal investigator 1 Organon LLC $1,235.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112365
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112379
Principal investigator 1 Organon LLC $1,235.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112393
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112405
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112419
Principal investigator 1 Organon LLC $1,235.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112433
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112449
Principal investigator 1 Organon LLC $1,235.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112461
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112475
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112489
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112503
Principal investigator 1 Organon LLC $1,235.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112517
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112533
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112547
Principal investigator 1 Organon LLC $1,235.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112561
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112575
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112589
Principal investigator 1 Organon LLC $2,304.00 10/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016112603
Principal investigator 1 Chiesi USA, Inc. $13,159.00 10/24/2023 Non-covered Recipient Entity
BCSD RESEARCH INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051612291
Principal investigator 1 Supernus Pharmaceuticals, Inc. $30,436.50 10/05/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5138 IN ADULTS WITH TREATMENT RESISTANT DEPRESSION No dispute reported 06/30/2026 1053193465
Principal investigator 1 Mylan Inc. $167.00 09/22/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1038724371
Principal investigator 1 Organon LLC $48,717.00 09/20/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016080713
Principal investigator 1 Chiesi USA, Inc. $25,410.00 09/11/2023 Non-covered Recipient Entity
BCSD RESEARCH INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051606843
Principal investigator 1 Supernus Pharmaceuticals, Inc. $11,980.40 09/08/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5138 IN ADULTS WITH TREATMENT RESISTANT DEPRESSION No dispute reported 06/30/2026 1053193093
Principal investigator 1 Organon LLC $67,882.50 08/23/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016119297
Principal investigator 1 Supernus Pharmaceuticals, Inc. $26,273.70 08/23/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5138 IN ADULTS WITH TREATMENT RESISTANT DEPRESSION No dispute reported 06/30/2026 1053192499
Principal investigator 1 Chiesi USA, Inc. $832.00 08/03/2023 Non-covered Recipient Entity
BCSD RESEARCH INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051604029
Principal investigator 1 Organon LLC $66,095.10 07/21/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016087965
Principal investigator 1 Supernus Pharmaceuticals, Inc. $41,291.62 07/06/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5138 IN ADULTS WITH TREATMENT RESISTANT DEPRESSION No dispute reported 06/30/2026 1053191871
Principal investigator 1 Chiesi USA, Inc. $5,696.00 07/03/2023 Non-covered Recipient Entity
BCSD RESEARCH INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051598019
Principal investigator 1 Genentech, Inc. $2,709.00 06/28/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1040241295
Principal investigator 1 Organon LLC $60,623.10 06/21/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016103365
Principal investigator 1 Supernus Pharmaceuticals, Inc. $2,995.10 06/08/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5138 IN ADULTS WITH TREATMENT RESISTANT DEPRESSION No dispute reported 06/30/2026 1053191509
Principal investigator 1 Chiesi USA, Inc. $2,928.00 06/06/2023 Non-covered Recipient Entity
LA SALUD RESEARCH CLINIC INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051595747
Principal investigator 1 Supernus Pharmaceuticals, Inc. $35,070.35 06/03/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5138 IN ADULTS WITH TREATMENT RESISTANT DEPRESSION No dispute reported 06/30/2026 1053191341
Principal investigator 1 Organon LLC $89,406.90 05/24/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016103319
Principal investigator 1 Chiesi USA, Inc. $16,496.00 05/08/2023 Non-covered Recipient Entity
BCSD RESEARCH INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051594501
Principal investigator 1 Chiesi USA, Inc. $10,160.00 05/08/2023 Non-covered Recipient Entity
BCSD RESEARCH INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051594505
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,755.67 04/28/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046570749
Principal investigator 1 GlaxoSmithKline, LLC. $9,784.95 04/19/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1006262809
Principal investigator 1 Organon LLC $114,482.70 04/19/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016120817
Principal investigator 1 Chiesi USA, Inc. $16,496.00 04/18/2023 Non-covered Recipient Entity
LA SALUD RESEARCH CLINIC INC
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1051593867
Principal investigator 1 Integrative Research Laboratories Sweden AB $4,238.85 04/05/2023 Non-covered Recipient Entity
Avantis Clinical Research, LLC
IRL790C005 No dispute reported 06/30/2026 993533197
Principal investigator 1 Supernus Pharmaceuticals, Inc. $15,255.90 03/29/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5138 IN ADULTS WITH TREATMENT RESISTANT DEPRESSION No dispute reported 06/30/2026 1053190155
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,755.67 03/21/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046568479
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,755.67 03/21/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046569487
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,439.77 03/21/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046569751
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,755.67 03/21/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046569769
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,755.67 03/21/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046570009
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,755.67 03/21/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046570047
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,439.77 03/21/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046571641
Principal investigator 1 Organon LLC $63,613.80 03/15/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016126905
Principal investigator 1 Supernus Pharmaceuticals, Inc. $21,557.72 03/09/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-5138 IN ADULTS WITH TREATMENT RESISTANT DEPRESSION No dispute reported 06/30/2026 1053189391
Principal investigator 1 GlaxoSmithKline, LLC. $325.20 03/03/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1006262821
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $100.00 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046568295
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $100.00 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046568335
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,439.77 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046568497
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $100.00 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046569503
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,439.77 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046569525
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,439.77 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046570029
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,889.33 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046570199
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,439.77 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046570217
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,755.67 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046570421
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,889.33 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046570441
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,755.67 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046570715
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,755.67 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046570731
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,439.77 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046571059
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,439.77 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046571373
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,889.33 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046571621
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,439.77 02/22/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046572663
Principal investigator 1 Organon LLC $75,217.50 02/17/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016126919
Principal investigator 1 Genentech, Inc. $8,000.00 02/01/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1040241305
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,889.33 01/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046568313
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,500.00 01/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046569733
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,889.33 01/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046570237
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $5,000.00 01/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046570447
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,889.33 01/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046571039
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,889.33 01/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046571077
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,889.33 01/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046571337
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $1,889.33 01/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046571355
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $6,500.00 01/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
A PHASE 23 DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED SAFETY AND EFFICACY TRIAL OF BHV3000 RIMEGEPANT ORALLY DISINTEGRATING TABLET ODT FOR THE ACUTE TREATMENT OF CHRONIC RHINOSINUSITIS CRS WITH OR WITHOUT NASAL POLYPS No dispute reported 06/30/2026 1046571653
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 01/25/2023 Non-covered Recipient Entity
AVANTIS CLINICAL RESEARCH LLC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1006262815
Principal investigator 1 Organon LLC $108,446.40 01/25/2023 Non-covered Recipient Entity
Avantis Clinical Research LLC
OG-8175A-023 No dispute reported 06/30/2026 1016126891